Who’s running this study?

I just received an interesting article from a colleague:
http://www.tampabay.com/news/business/article463686.ece

Was the Principal Investigator Providing adequate oversight?

The article discusses a clinical research unit in Florida where the PI oversight isn’t exactly verifiable. This is always an issue for us as monitors, especially when the Dr. practices from one location and the study is conducted in another. I apply extra scrutiny in this case to ensure everything is in order and that the data isn’t “too perfect” (do the subjects even exist? qualify? are they being followed properly as per protocol?, etc.)

Can the Principal Investigator delegate to others?

As a monitor, it is helpful when a sponsor will pin down (before conduct begins) exactly which actions can be delegated (lab draws, EKG, etc) and which actions must be reserved for the PI or medically licensed personnel. In many studies, the assessment of Inclusion/Exclusion Criteria, Physical Exams, Dose escalations/de-escalations, and Lab/safety reviews are responsibilities that must be reserved for the physician. It is best if this is written in a statement on the Delegation of Authority Log but I take what I can get and always include this as a topic at site selection and initiation visits.

Does the Principal Investigator have the bandwidth?

I prefer to work with sites where the PI is highly involved but as monitors we don’t always get that choice and the quality of the data can suffer. However, I recently worked with a site that enrolled almost 30 subjects in one month. They were the highest enroller and the numbers shocked everyone — I immediately suspected that the PI may not have been very involved in the conduct due to the volume and time commitment that would require. The site had been initiated at the IM so by the time I had my first visit, they had enrolled over 10 subjects in this 7 week study. I conducted 4 routine monitoring visits over the 2 months and even brought co-monitors with me to handle the volume and “sniff out the deficiencies”. At each visit the PI was available and very informed about his subjects and was constantly asking me to go back to the sponsor for clarifications on the protocol and to discuss changes he witnessed in his patient’s lab values. My instincts were good but the reality is this PI was also very good and very involved in the oversight and conduct of the trial so I had nothing to worry about after all. The site was organized, fast at CRF entry/query resolution, and thorough. I would work with the site again in a heartbeat. That just goes to show that you don’t always have to compromise quality when you have quantity.

Check in regularly with the coordinator and watch the workload

On the other hand, I had a few other high enrollers in this study where PI oversight would have gone a long way to improving conduct. So the takeaway here is be especially wary when the PI is MIA and you have an over-zealous coordinators who always reassures you that “it’s fine” ,”I’m handling it”, “oh really, I didn’t realize the protocol meant it that way…” and other red flag statements. Make sure the PI is available to meet with you at every visit. If you have had 2 visits in a row where the PI isn’t around, escalate it to your lead CRA or the sponsor or refer to your SOPs. When an investigator signs a 1572, that is a legal contract that they agree to personally oversee the conduct of the trial. If you aren’t satisfied that this is happening, document it in your report and follow-up via phone or meet with the PI to discuss your concerns. It is an uncomfortable conversation but that is one of your responsibilities as a monitor. I know from experience that this conversation is easier to have in the beginning rather than at the last visit before data lock, or when it is time to sign off on the casebook, or even after a (gulp) sponsor or FDA audit.

Routine Monitoring Visits
Close-Out Visits
About The Author

The Lead CRA

Nadia started The Lead CRA blog in 2007. She is now lead author for ClinOps Toolkit. Nadia is currently working as a Clinical Program Manager at a small specialty pharmaceutical company in the San Francisco Bay Area. You can reach Nadia via email at leadcra@clinopstoolkit.com anytime.

4 Comments

  • The Lead CRA

    The Lead CRA

    August 12, 2008

    Vesmi,
    Thanks for your question but I am no lawyer! I don’t have children either so I have not encountered this situation. I do however, have dogs and I am careful not to let them bark in the background on calls because I think that is very unprofessional. You could talk to HR and find out what your official telecommuter policy states on the matter. My employer actually has a policy that we are all required to read and sign off on. It does say “working from home is not a substitute for appropriate child care.” In other words, my company considers that you are being paid to do a job and anything that might distract you from being as productive as possible is a no no. I am sorry that is probably not what you wanted to hear but I encourage you to acquaint yourself with the relevant policies at your firm. Hope that helps!

  • Vesmi

    August 12, 2008

    I am a CRA regional. I had an unexpected phone call from my manager one day at home and my Manager once questioned me why do I have my child at home with me and not in Day care in a nasty demeaning tone? She heard my child in the background. My work is above average and I have very high standards
    Is this legal for a manager to say this. What can I do. It is so uncomfortable to talk with her.

    Vesmi

  • Anonymous

    July 3, 2008

    Great Blog! I hope you will posting on it!

    (from a junior CRA)

  • Anonymous

    June 5, 2008

    Good advice! We do the best we can to ensure that patients have access to medical supervision. As CRAs we can not be at the sites all the time. We just have to be careful and ask questions that confirm that the protocol is being conducted correctly according to GCP and ICH standards.

Leave A Response